Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports BY Vandana Singh • October 1, 2026October 2, 2026 Novo Nordisk A/S (NYSE:NVO) on Thursday presented a post hoc analysis from a STEP UP trial sub-population, indicating that Wegovy (pooled semaglutide 7.2 and 2.4 mg) effectively reduced liver fat in o[...] Read more
